Gemtuzumab Ozogamicin Access & Import Assistance India

Gemtuzumab Ozogamicin (Mylotarg) used for targeted AML therapy through the Named Patient Program in India.

Accessing advanced therapies for Acute Myeloid Leukemia (AML) in India can be difficult, especially since it is not widely available through local pharmaceutical channels. Gemtuzumab Ozogamicin (brand name Mylotarg) is a specialized CD33-targeted antibody-drug conjugate (ADC) designed to selectively attack leukemia cells by delivering a potent cytotoxic compound directly to them. For patients who require this therapy, the Indian healthcare system allows regulated access through approved international procurement pathways when local availability is limited.

What is the Named Patient Program?

The Named Patient Program is a legally permitted procedure that enables patients to access medicines that have not yet received full commercial authorization in India. Governed under Rule 36 of the Drugs & Cosmetics Rules, 1945, this program allows import of medicines for treatment of serious or life-threatening conditions such as cancer. This pathway is particularly important for patients who urgently need innovative therapies that are not currently marketed domestically. The process operates under the supervision of the Central Drugs Standard Control Organisation (CDSCO) to ensure compliance with Indian pharmaceutical import regulations and patient safety requirements.

Eligibility for Ordering

Patients may qualify to receive Gemtuzumab Ozogamicin by 24/7 Quality Meds when a licensed oncologist or hematologist confirms that the therapy is medically necessary for the individual case. This therapy is indicated for the treatment of CD33-positive AML, including certain newly diagnosed, relapsed, or refractory cases in both adults and eligible pediatric patients. The treating physician must assess the patient’s clinical condition and determine that access to this therapy is essential, particularly when suitable locally available alternatives are inadequate or unavailable. A formal prescription and medical justification are generally required as part of the approval process.

Step-by-Step Ordering Process

The ordering procedure begins with the preparation of essential medical and identification documents. A properly issued doctor’s prescription must include the medicine name, diagnosis, dosage instructions, duration of therapy, doctor’s registration number, signature, and hospital stamp. Patients are also required to submit recent medical records, pathology or diagnostic reports, and valid identity and address proof such as an Aadhaar card or passport. Following document verification, an application is processed through the CDSCO import approval system, typically involving Form 12A and Form 12B. Once regulatory clearance is obtained, the medicine is sourced from authorized global suppliers and transported under controlled cold-chain storage conditions (2°C–8°C) to preserve product quality and therapeutic effectiveness.

Access Support

247QualityMeds assists patients and healthcare professionals with the procurement process for imported oncology medicines through the Named Patient Program pathway. We provide services including guidance with documentation, coordination with verified international suppliers, compliance monitoring, and management of temperature-controlled logistics. Medicines are generally sourced through suppliers that follow recognized international quality and distribution standards, helping ensure safe, compliant, and reliable access for AML patients requiring specialized treatment.